Subclinical Hyperthyroidism

📋 Key Information Summary

📋

Subclinical hyperthyroidism (SCH) is defined as a suppressed TSH (<0.4 mU/L) with free T4 (FT4) and free T3 (FT3) within the normal reference range.
SCH is classified as mild (TSH 0.1–0.4 mU/L) or severe (TSH <0.1 mU/L) — severe SCH carries greater cardiovascular and skeletal risk.
Prevalence in Australia is approximately 0.7–1.5 %, increasing with age and iodine-supplement use.
Exogenous causes (suppressed TSH from levothyroxine over-replacement) are more common than endogenous causes (toxic nodular goitre, Graves' disease) in treated populations.
Key clinical risks include atrial fibrillation (2–5× increased risk), osteoporosis and fractures (especially postmenopausal women), and increased cardiovascular mortality.
Investigation requires confirmation of suppressed TSH on at least two occasions 4–8 weeks apart, plus FT4, FT3, thyroid antibodies (TPOAb, TRAb), and thyroid ultrasound with Doppler.
Thyroid scintigraphy (technetium-99m pertechnetate scan) is indicated when aetiology is unclear or toxic nodular disease is suspected.
Treatment is generally recommended for severe SCH (TSH <0.1 mU/L) in patients ≥65 years, postmenopausal women, or those with cardiac disease or osteoporosis risk.
Treatment options include antithyroid drugs (carbimazole, propylthiouracil), radioiodine (I-131), or surgery depending on aetiology and patient factors.
For exogenous SCH from levothyroxine over-replacement, dose reduction of levothyroxine is first-line management.
Mild SCH in younger, asymptomatic patients can often be observed with annual TSH monitoring.
Aboriginal and Torres Strait Islander peoples may have later presentation and limited access to specialist endocrinology services in remote areas.

🎧 Audio Brief

How Hair Vitamins Mimic Thyroid Disease

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Introduction & Australian Epidemiology

Subclinical hyperthyroidism (SCH) is a biochemical state characterised by a suppressed thyroid-stimulating hormone (TSH) concentration below the lower limit of the reference range (<0.4 mU/L), with serum free thyroxine (FT4) and free triiodothyronine (FT3) remaining within their respective normal ranges. Patients may be asymptomatic or exhibit subtle features of thyroid hormone excess such as palpitations, anxiety, tremor, heat intolerance, or weight loss.

SCH is clinically important because it is not a benign laboratory finding. Even in the absence of overt symptoms, the chronically suppressed TSH state places patients at elevated risk of atrial fibrillation, osteoporotic fractures, and cardiovascular morbidity and mortality — risks that are amplified with advancing age and a TSH <0.1 mU/L.

In Australia, population-based data from the Busselton Health Study and the nationally representative Australian Health Survey suggest an SCH prevalence of approximately 0.7–1.5 %, with higher rates observed in iodine-replete areas and among older women. The introduction of mandatory iodine fortification of bread in 2009 (FSANZ Standard 2.1.1) has been associated with a modest increase in thyroid dysfunction detection rates, including SCH, in some surveillance programmes.

Distinguishing endogenous SCH (autonomous thyroid hormone production) from exogenous SCH (iatrogenic levothyroxine over-replacement) is critical, as the management pathways diverge significantly.

Epidemiology & Causes

Epidemiology

Large cohort studies demonstrate that SCH affects 0.5–4 % of adults globally, with prevalence varying by assay sensitivity, TSH cut-off, and iodine intake. Australian data are broadly consistent:

Population	Prevalence	Key Notes
General Australian adults	0.7–1.5 %	Higher in women, increasing with age
Women >60 years	2–4 %	Predominantly multinodular goitre-related
Post-levothyroxine patients	5–20 %	Most common iatrogenic cause in Australia
Iodine-fortified populations	1.0–2.5 %	Post-2009 FSANZ mandate data

Endogenous Causes

Toxic multinodular goitre (TMNG): The most common endogenous cause in Australia, particularly in older patients in iodine-marginal regions. Autonomous nodules produce thyroid hormone independently of TSH.
Graves' disease: An autoimmune cause mediated by TSH-receptor antibodies (TRAb). May present with SCH in early or treated-remission phases.
Toxic adenoma (solitary): A single autonomously functioning nodule with somatic TSH-receptor or Gsα mutations.
Subacute thyroiditis (De Quervain's): Transient SCH may occur during the thyrotoxic phase of viral thyroiditis.
Iodine-induced (Jod-Basedow phenomenon): Occurs with iodinated contrast, amiodarone, or excessive iodine supplementation in patients with underlying autonomous thyroid tissue.

Exogenous Causes

Levothyroxine over-replacement: Very common in clinical practice. Many patients on T4 replacement are maintained with TSH <0.4 mU/L unintentionally.
Exogenous thyroid hormone abuse: Rare; occasionally seen in eating disorders or bodybuilding contexts.
Biotin interference: High-dose biotin supplements (>5 mg/day) can cause artefactual TSH suppression on immunoassay platforms — important to check supplements before diagnosing SCH.

⚠️

Biotin warning: Patients taking high-dose biotin supplements (common in over-the-counter hair/nail products) may show falsely low TSH on competitive immunoassays. Advise patients to cease biotin for 48–72 hours before thyroid function testing.

Clinical Risks — AF, Osteoporosis & Cardiovascular

The clinical significance of SCH lies primarily in its long-term adverse outcomes. Even mild SCH (TSH 0.1–0.4 mU/L) is associated with measurable increases in cardiovascular and skeletal morbidity, while severe SCH (TSH <0.1 mU/L) confers substantially greater risk.

Mild SCH

TSH 0.1–0.4 mU/L

Modest increase in AF risk (1.5–2×), trend toward increased bone loss in postmenopausal women, generally asymptomatic or subtle symptoms.

Setting: GP monitoring, consider treatment in at-risk groups

Severe SCH

TSH <0.1 mU/L

Markedly elevated AF risk (3–5×), significant bone mineral density loss (especially cortical bone), increased cardiovascular mortality, potential cognitive decline in elderly.

Setting: Specialist referral recommended, treatment usually indicated

Atrial Fibrillation

SCH is an independent risk factor for atrial fibrillation (AF). The Framingham Heart Study demonstrated a 3-fold increase in AF incidence over 10 years in participants with TSH <0.1 mU/L, even after adjustment for age, sex, and traditional cardiac risk factors. In the Rotterdam Study, the risk was 3.1× for severe SCH and 1.5× for mild SCH. This has direct implications for anticoagulation decisions under the CHA₂DS₂-VASc scoring system.

Osteoporosis & Fractures

Excess thyroid hormone accelerates bone turnover, favouring resorption over formation. In postmenopausal women, SCH (particularly severe) is associated with a 2–4-fold increased risk of hip and vertebral fractures. Bone mineral density (BMD) loss is most pronounced at cortical bone sites (distal radius, femoral neck). The National Osteoporosis Guideline (RACGP-endorsed) recommends consideration of SCH in the workup of unexplained osteoporosis.

Cardiovascular Mortality

Meta-analyses (Collet et al., 2012; Gencer et al., 2012) pooling over 500,000 person-years of follow-up demonstrate a 24–41 % increase in total mortality and a significant increase in cardiovascular mortality in individuals with TSH <0.1 mU/L. Mechanisms include enhanced sympathetic activation, increased systemic vascular resistance, left ventricular hypertrophy, and endothelial dysfunction.

🚨

Clinical priority: Severe SCH (TSH <0.1 mU/L) in patients ≥65 years is a treatable risk factor for AF, heart failure, and cardiovascular death. Delayed recognition and management contributes to preventable morbidity.

Other Associated Risks

Cognitive impairment: Emerging evidence links SCH in the elderly with increased risk of dementia, particularly Alzheimer's disease.
Muscle weakness: Proximal myopathy may occur, increasing fall risk in older adults.
Heart failure: SCH is associated with increased risk of congestive heart failure, particularly in those with pre-existing cardiac disease.

Investigations

Initial & Confirmatory Biochemistry

A single suppressed TSH result is not sufficient for diagnosis. SCH should be confirmed with repeat thyroid function testing (TSH, FT4, FT3) at 4–8 weeks.

Essential

TSH (ultra-sensitive assay)

MBS Item 66716. Confirms suppressed TSH (<0.4 mU/L). Repeat at 4–8 weeks for confirmation. Available at all Australian pathology laboratories.

Essential

Free T4 (FT4)

MBS Item 66716 (bundled with TSH). Must be within the normal reference range for SCH diagnosis. If elevated → overt hyperthyroidism.

Available

Free T3 (FT3)

MBS Item 66719. Usually within normal range in SCH. Useful to differentiate from T3 thyrotoxicosis.

Available

TSH-Receptor Antibodies (TRAb)

MBS Item 66840. Indicated when Graves' disease is suspected. Available through major Australian laboratories. Useful to differentiate autoimmune from nodular causes.

Available

Thyroid Peroxidase Antibodies (TPOAb)

MBS Item 66838. Supports autoimmune aetiology. Positive in approximately 50–80 % of Graves' disease.

Imaging

Available

Thyroid Ultrasound with Doppler

MBS Item 55509. First-line imaging. Identifies nodularity, estimates gland volume, assesses vascularity (increased in Graves'). Bulk-billed at most radiology practices.

Referral

Thyroid Scintigraphy (Tc-99m or I-123)

MBS Item 61407. Nuclear medicine scan — indicated when nodular disease is present and differentiation of toxic adenoma from TMNG is needed, or when TRAb is negative and aetiology unclear. Availability limited to metropolitan and major regional centres.

Additional Investigations for Risk Assessment

Available

Electrocardiogram (ECG)

Baseline ECG to screen for AF, especially in patients ≥65 years or with palpitations. Available universally.

Available

DEXA Scan (Bone Mineral Density)

MBS Item 12320. Indicated for postmenopausal women and men ≥50 years with SCH, as per Osteoporosis Australia and RACGP guidelines.

Available

24-hour Holter Monitor

For intermittent palpitations or suspected paroxysmal AF. Refer to cardiology if indicated.

⚠️

Biotin interference check: Before confirming SCH, ask patients about biotin supplement use. High-dose biotin (>5 mg/day) can falsely lower TSH on competitive immunoassays (e.g., Roche, Abbott). Instruct patients to cease biotin for 48–72 hours before retesting.

Treatment Indications & Management

When to Treat

Not all patients with SCH require immediate treatment. The decision to intervene depends on TSH severity, patient age, comorbidities, and symptom burden. The following framework guides clinical decision-making:

1

Confirm SCH

Repeat TFTs at 4–8 weeks. Confirm TSH <0.4 mU/L with normal FT4/FT3. Rule out biotin interference and assay artefacts.

2

Determine Aetiology

Exogenous (levothyroxine dose adjustment) vs. endogenous (Graves', TMNG, toxic adenoma). Perform TRAb and thyroid ultrasound as indicated.

3

Assess Severity

Mild (TSH 0.1–0.4) vs. severe (TSH <0.1). Severe SCH generally warrants treatment; mild SCH may be observed.

4

Evaluate Risk Factors

Age ≥65, AF history, heart failure, osteoporosis, postmenopausal status, cardiovascular risk factors.

5

Decide: Treat or Observe

Treatment indicated for severe SCH with risk factors. Mild SCH without risk factors: annual TSH monitoring with GP review.

Treatment Indications Summary

Scenario	Recommendation	Evidence Level
TSH <0.1 + age ≥65 or cardiac disease	Treat	Strong (observational, meta-analyses)
TSH <0.1 + postmenopausal woman	Treat	Strong
TSH <0.1 + osteoporosis or high fracture risk	Treat	Strong
TSH 0.1–0.4 + symptomatic	Consider treatment	Moderate
TSH 0.1–0.4 + age <65, asymptomatic, no risk factors	Observe (annual TSH)	Moderate
Exogenous SCH (levothyroxine over-replacement)	Dose reduction	Strong (standard of care)

Management: Exogenous SCH (Levothyroxine Over-Replacement)

This is the most common scenario in clinical practice. Management is straightforward:

Reduce levothyroxine dose by 12.5–25 mcg/day.
Recheck TSH at 6–8 weeks.
Target TSH: 0.4–2.5 mU/L for most patients (0.5–3.0 mU/L for elderly).
For thyroid cancer patients on TSH-suppressive therapy, discuss risk-benefit with an endocrinologist.

Management: Endogenous SCH

Treatment of endogenous SCH depends on the underlying aetiology:

Graves' Disease–Related SCH

💊

Carbimazole

Neo-Mercazole® · Antithyroid (thionamide)

Adult dose 5–15 mg PO daily (lower dose for SCH vs. overt hyperthyroidism)

Paediatric dose 0.5–1 mg/kg/day; commence at higher end, titrate down

Route/Frequency Oral, once daily

Duration 12–18 months (titration regimen) or until remission

Renal adjustment No dose adjustment required

Hepatic adjustment Use with caution; monitor LFTs at baseline and if symptoms arise

PBS status ✔ PBS General Benefit

💊

Propylthiouracil (PTU)

Propycil® · Antithyroid (thionamide)

Adult dose 50–100 mg PO TDS (lower end for SCH)

Paediatric dose 5–7 mg/kg/day in divided doses (TDS)

Route/Frequency Oral, three times daily

Duration 12–18 months; generally reserved for first trimester pregnancy or carbimazole intolerance

Renal adjustment No dose adjustment required

Hepatic adjustment Caution — risk of idiosyncratic hepatotoxicity; monitor LFTs

PBS status ✔ PBS General Benefit

Toxic Nodular Goitre (TMNG or Toxic Adenoma)

Antithyroid drugs achieve remission less reliably in nodular disease and are generally used as a bridge to definitive therapy:

Radioiodine (I-131): First-line definitive treatment for toxic nodular goitre in Australia. MBS Item 14065. Requires thyroid scintigraphy for pre-treatment planning. Commonly performed at nuclear medicine departments in metropolitan and selected regional centres. Hypothyroidism is the most common long-term outcome.
Surgery (thyroidectomy): Indicated for large goitres causing compressive symptoms, suspected malignancy, or when radioiodine is contraindicated. Refer to an endocrine surgeon.

Beta-Blockers for Symptom Control

💊

Propranolol

Inderal® · Beta-blocker (non-selective)

Adult dose 10–40 mg PO TDS–QDS for symptomatic relief

Route/Frequency Oral, 3–4 times daily

Renal adjustment No adjustment required

PBS status ✔ PBS General Benefit

💊

Atenolol

Noten® · Beta-blocker (β1-selective)

Adult dose 25–50 mg PO daily

Route/Frequency Oral, once daily

Renal adjustment Reduce dose if eGFR <35 mL/min

PBS status ✔ PBS General Benefit

Monitoring on Treatment

TSH, FT4, FT3 at 4–6 weeks after commencing or adjusting antithyroid therapy.
Once stable, monitor every 3–6 months during the treatment course.
FBC (particularly WCC with differential) at baseline and if symptoms of agranulocytosis develop — instruct patients to present urgently if sore throat, fever, or mouth ulcers occur.
LFTs at baseline for carbimazole and PTU; repeat if hepatic symptoms.
Annual ECG and DEXA scan in at-risk populations as per risk assessment.

🚨

Agranulocytosis warning: Both carbimazole and PTU carry a 0.1–0.5 % risk of agranulocytosis (WCC <0.5 × 10⁹/L), typically occurring in the first 3 months. All patients must receive written and verbal counselling to cease the drug immediately and attend emergency if fever, sore throat, or oral ulceration develops. Baseline FBC is essential before commencing therapy.

Special Populations

🤰 Pregnancy

Carbimazole: Avoid in first trimester if possible (associated with aplasia cutis, choanal atresia). May be used in second/third trimester at lowest effective dose.

Propylthiouracil: Preferred in first trimester. Switch to carbimazole after 16 weeks if needed due to hepatotoxicity risk.

Radioiodine: Contraindicated in pregnancy. Ensure pregnancy test before I-131. Avoid conception for 6 months post-treatment.

SCH in pregnancy is managed under specialist endocrinology and obstetric care. Target TSH: trimester-specific reference ranges.

👶 Paediatrics

Carbimazole: 0.5–1 mg/kg/day, titrate down. Monitor growth, weight, and behaviour.

PTU: 5–7 mg/kg/day in divided doses. Second-line due to hepatotoxicity risk.

Referral to a paediatric endocrinologist is recommended for all children with SCH. Monitor bone age and growth velocity.

👴 Elderly (≥65 years)

SCH in the elderly carries the highest cardiovascular risk. AF and heart failure are common complications.

Antithyroid drugs: Use lower doses and titrate cautiously. Monitor for drug interactions (e.g., warfarin potentiation).

Radioiodine is often preferred as definitive therapy in the elderly for TMNG. Beta-blockers used with caution due to bradycardia and hypotension risk.

🫘 Renal Impairment

Carbimazole / PTU: No significant renal dose adjustment needed; these are hepatically metabolised.

Atenolol: Reduce dose if eGFR <35 mL/min.

Monitor closely for fluid overload and electrolyte disturbance in CKD patients with hyperthyroidism.

🫁 Hepatic Impairment

Carbimazole: Use with caution; monitor LFTs closely.

PTU: Higher hepatotoxicity risk — use with extreme caution in pre-existing liver disease. Consider carbimazole as alternative, with monitoring.

Radioiodine may be preferred over antithyroid drugs in significant hepatic impairment.

🛡️ Immunocompromised

Antithyroid drugs carry a risk of agranulocytosis, which is particularly dangerous in immunocompromised patients.

Monitor FBC more frequently (every 2 weeks for first 3 months).

Consider early definitive therapy (radioiodine or surgery) to minimise prolonged drug exposure.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

Thyroid disorders in Aboriginal and Torres Strait Islander peoples are under-diagnosed and under-researched. Remote and very remote communities face particular challenges in accessing timely thyroid function testing, specialist endocrinology review, and definitive therapies such as radioiodine or surgery.

Remote access

Nuclear medicine and endocrinology services are concentrated in metropolitan centres. Radioiodine therapy requires travel to regional or capital city facilities, imposing significant logistical, financial, and cultural barriers for remote communities.

Later presentation

Aboriginal and Torres Strait Islander patients may present later with larger goitres, more advanced nodular disease, and complications such as AF or heart failure. Lower literacy about thyroid symptoms may contribute.

Iodine status

Some remote communities remain iodine-deficient despite national fortification. Iodine deficiency increases the prevalence of nodular thyroid disease and associated SCH.

Cultural safety

Clinicians should engage with Aboriginal Health Workers and use culturally appropriate communication strategies. Telehealth endocrinology consultations can improve access but require reliable connectivity.

Pathology availability

Access to thyroid function testing (MBS Item 66716) and TRAb testing may be delayed in remote pathology services with specimen transport times of 24–48 hours to reference laboratories.

Medication adherence

Long courses of antithyroid drugs require sustained adherence. Remote pharmacy access and medication supply chains can be disrupted. Single-dose daily regimens (carbimazole) may be preferable to TDS regimens (PTU).

Clinicians should refer to the AIHW "Aboriginal and Torres Strait Islander Health Performance Framework" and the RACGP "National Guide to a Preventive Health Assessment for Aboriginal and Torres Strait Islander People" for comprehensive screening and management guidance.

📚 References

1. Biondi B, Cooper DS. Subclinical hyperthyroidism. N Engl J Med. 2018;378(25):2411–2419. doi:10.1056/NEJMcp1709318
2. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421. doi:10.1089/thy.2016.0229
3. Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172(10):799–809. doi:10.1001/archinternmed.2012.402
4. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040–1049. doi:10.1161/CIRCULATIONAHA.112.096024
5. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotrophic concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249–1252. doi:10.1056/NEJM199411103311901
6. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework 2020 summary report. Canberra: AIHW; 2020.
7. Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. [Note: Replaced with more relevant thyroid reference below]
7. The Royal Australian College of General Practitioners (RACGP). National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people. 3rd ed. Melbourne: RACGP; 2018.
8. Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018;7(4):167–186. doi:10.1159/000490384
9. Food Standards Australia New Zealand (FSANZ). Fortification of bread with iodine — final assessment report, Proposal P1003. Canberra: FSANZ; 2008.
10. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295(9):1033–1041. doi:10.1001/jama.295.9.1033
11. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
12. Waung JA, Bassett JHD, Williams GR. Thyroid hormone metabolism in skeletal development and adult bone maintenance. Trends Endocrinol Metab. 2012;23(4):155–162. doi:10.1016/j.tem.2011.12.002